CZMWF
Carl Zeiss Meditec AG
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
36.56
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
36.56
Prev close
36.56
Day high
32.76
Day low
32.76
Volume
150
Market cap
$3.20B
P/E (TTM)
22.85
52W range
26.42 – 55.75
Day trading desk
Gap from prior close
-0.00%
Prior close 36.56
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
36.56 – 36.56
Position in range
—
—
ATR (14D)
0.68
1.86% of price
Prior day high
36.56
PDH
Prior day low
36.56
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 129
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+8.71%
+10.1%
1M
+9.13%
+5.4%
3M
+18.62%
+15.5%
6M
+10.29%
-0.8%
YTD
-24.93%
-37.2%
1Y
-24.32%
-44.3%
3Y
-64.85%
-139.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CZMWF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
51.04M
Total on file
Fundamentals
Market cap$3.20B
Enterprise value$3.72B
Revenue (TTM)$2.18B
Gross profit$1.12B
EBITDA$217.84M
Net income$121.51M
EPS (TTM)$1.60
Free cash flow—
Total cash$23.90M
Total debt$580.95M
Book value / share$28.02
Shares outstanding87.54M
Float34.19M
Short % of float—
Dividend yield1.72%
Beta (5Y)1.35
Valuation & profitability ratios
Trailing P/E22.85
Forward P/E14.01
PEG ratio1.08
Price / sales—
Price / book1.30
EV / revenue1.71
EV / EBITDA17.08
Gross margin51.56%
Operating margin11.06%
Profit margin5.57%
Return on equity—
Return on assets—
Debt / equity27.56
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.23B | $2.07B | $2.09B | $1.90B | +7.8% |
| Operating revenue | $2.23B | $2.07B | $2.09B | $1.90B | +7.8% |
| Cost of revenue | $1.05B | $977.50M | $883.53M | $775.24M | +7.7% |
| Gross profit | $1.18B | $1.09B | $1.21B | $1.13B | +8.0% |
| Research & development | $326.27M | $343.09M | $349.28M | $291.37M | -4.9% |
| Selling, general & admin | $626.52M | $569.21M | $504.06M | $438.06M | +10.1% |
| Total operating expense | $951.88M | $894.18M | $857.64M | $730.72M | +6.5% |
| Operating income | $223.32M | $194.45M | $348.12M | $396.88M | +14.8% |
| Net interest income | -$19.00M | $37.85M | $27.13M | $55.24M | -150.2% |
| Pre-tax income | $193.89M | $240.87M | $412.56M | $403.49M | -19.5% |
| Tax provision | $51.55M | $60.71M | $120.56M | $107.58M | -15.1% |
| Net income | $141.21M | $178.73M | $290.40M | $293.91M | -21.0% |
| Net income to common | $141.21M | $178.73M | $290.40M | $293.91M | -21.0% |
| Basic EPS | 1.61 | 2.01 | 3.25 | 3.29 | -19.9% |
| Diluted EPS | 1.61 | 2.01 | 3.25 | 3.29 | -19.9% |
| EBIT | $220.52M | $270.29M | $427.81M | $413.08M | -18.4% |
| EBITDA | $346.89M | $403.06M | $501.88M | $482.85M | -13.9% |
| Basic shares | 87.54M | 88.85M | 89.44M | 89.44M | -1.5% |
| Diluted shares | 87.54M | 88.85M | 89.44M | 89.44M | -1.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $27.27M | $20.29M | $10.60M | $7.73M | +34.4% |
| Cash & short-term investments | $27.27M | $20.29M | $10.60M | $7.73M | +34.4% |
| Accounts receivable | $209.01M | $209.05M | $196.92M | $197.80M | -0.0% |
| Inventory | $496.98M | $536.16M | $519.62M | $382.75M | -7.3% |
| Total current assets | $1.27B | $1.21B | $1.91B | $1.79B | +5.3% |
| Property, plant & equipment | $342.95M | $353.76M | $315.77M | $236.15M | -3.1% |
| Goodwill & intangibles | $1.63B | $1.69B | $675.27M | $670.08M | -3.4% |
| Total assets | $3.40B | $3.39B | $3.03B | $2.82B | +0.3% |
| Total current liabilities | $543.81M | $568.84M | $561.65M | $539.32M | -4.4% |
| Total debt | $132.46M | $151.35M | $155.70M | $127.90M | -12.5% |
| Total liabilities | $1.28B | $1.34B | $860.02M | $792.73M | -4.6% |
| Retained earnings | $1.58B | $1.49B | $1.41B | $1.21B | +6.0% |
| Shareholder equity | $2.12B | $2.04B | $2.16B | $2.02B | +3.7% |
| Working capital | $728.13M | $639.09M | $1.35B | $1.25B | +13.9% |
| Net tangible assets | $483.89M | $352.34M | $1.48B | $1.35B | +37.3% |
| Shares issued | 89.44M | 89.44M | 89.44M | 89.44M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $142.34M | $180.15M | $292.01M | $295.91M | -21.0% |
| Depreciation & amortisation | $126.38M | $132.77M | $74.06M | $69.77M | -4.8% |
| Change in working capital | -$36.67M | $15.10M | -$125.88M | -$109.51M | -342.8% |
| Operating cash flow | $209.86M | $247.32M | $250.86M | $188.20M | -15.1% |
| Capital expenditure | -$76.59M | -$152.20M | -$113.86M | -$81.97M | +49.7% |
| Investing cash flow | -$91.03M | -$412.31M | -$110.98M | -$92.89M | +77.9% |
| Share buybacks | $0 | -$150.07M | $0 | — | +100.0% |
| Dividends paid | -$52.52M | -$98.20M | -$98.39M | -$80.50M | +46.5% |
| Financing cash flow | -$108.83M | $176.25M | -$135.09M | -$94.24M | -161.7% |
| Free cash flow | $133.26M | $95.11M | $137.00M | $106.23M | +40.1% |
| End cash position | $27.27M | $20.29M | $10.60M | $7.73M | +34.4% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $467.00M | $627.54M | $549.63M | $560.02M | $490.50M | -25.6% |
| Operating revenue | $467.00M | $627.54M | $549.63M | $560.02M | $490.50M | -25.6% |
| Cost of revenue | $239.80M | $295.75M | $260.03M | $258.28M | $238.40M | -18.9% |
| Gross profit | $227.10M | $331.70M | $289.70M | $301.73M | $252.10M | -31.5% |
| Research & development | $75.50M | $91.78M | $81.43M | $75.59M | $77.50M | -17.7% |
| Selling, general & admin | $150.60M | $169.62M | $154.36M | $153.87M | $148.70M | -11.2% |
| Total operating expense | $226.10M | $260.58M | $236.64M | $230.55M | $224.10M | -13.2% |
| Operating income | $1.00M | $71.12M | $53.06M | $71.18M | $28.00M | -98.6% |
| Net interest income | -$6.40M | -$4.89M | -$5.59M | -$3.34M | -$5.20M | -30.7% |
| Pre-tax income | -$5.40M | $67.19M | $41.23M | $65.38M | $20.10M | -108.0% |
| Tax provision | $200.00K | $13.05M | $13.51M | $19.75M | $5.20M | -98.5% |
| Net income | -$4.90M | $51.81M | $28.38M | $45.33M | $15.70M | -109.5% |
| Net income to common | -$4.90M | $51.81M | $28.38M | $45.33M | $15.70M | -109.5% |
| Basic EPS | -0.06 | — | — | 0.52 | 0.18 | — |
| Diluted EPS | -0.06 | — | — | 0.52 | 0.18 | — |
| EBIT | $2.00M | $73.52M | $47.66M | $72.39M | $27.00M | -97.3% |
| EBITDA | $2.00M | $73.52M | $47.66M | $72.39M | $27.00M | -97.3% |
| Basic shares | 81.67M | — | — | 87.17M | 87.22M | — |
| Diluted shares | 81.67M | — | — | 87.17M | 87.22M | — |
| Line item | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $27.27M | $26.55M | +2.7% |
| Cash & short-term investments | $27.27M | $51.45M | -47.0% |
| Accounts receivable | $209.01M | $183.59M | +13.9% |
| Inventory | $496.98M | $551.02M | -9.8% |
| Total current assets | $1.27B | $1.28B | -1.0% |
| Property, plant & equipment | $342.95M | $356.32M | -3.8% |
| Goodwill & intangibles | $1.63B | $1.69B | -3.3% |
| Total assets | $3.40B | $3.47B | -2.0% |
| Total current liabilities | $543.81M | $628.49M | -13.5% |
| Total debt | $132.46M | $146.87M | -9.8% |
| Total liabilities | $1.28B | $1.38B | -7.9% |
| Retained earnings | $1.58B | $1.49B | +5.4% |
| Shareholder equity | $2.12B | $2.08B | +2.0% |
| Working capital | $728.13M | $655.99M | +11.0% |
| Net tangible assets | $483.89M | $387.93M | +24.7% |
| Shares issued | 89.44M | 89.44M | 0.0% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Operating cash flow | $16.70M | $144.16M | $57.19M | $34.81M | -$26.30M | -88.4% |
| Investing cash flow | $700.00K | -$98.93M | $23.39M | $2.11M | -$17.60M | +100.7% |
| Financing cash flow | -$16.90M | -$50.83M | -$71.86M | -$36.24M | $50.10M | +66.7% |
| Free cash flow | $16.70M | $67.56M | $97.79M | -$5.79M | -$26.30M | -75.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $615.33M | -2.0% |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $2.18B | -2.2% |
| Next year | — | — | $2.29B | +4.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders59.14%
Held by institutions17.81%
Institutions holding179
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
35.37
+3.37% from price
SMA 20
34.82
+5.00% from price
SMA 50
33.00
+10.79% from price
SMA 100
31.92
+14.55% from price
SMA 200
36.26
+0.83% from price
EMA 12
35.39
+3.32% from price
EMA 26
34.54
+5.86% from price
EMA 50
33.58
+8.87% from price
RSI (14)
65.7
Neutral
MACD (12,26,9)
0.85
Hist 0.15
ATR (14)
0.68
1.86% of price
Realised vol 30D
38.9%
Annualised
Bollinger upper
37.15
20, 2σ
Bollinger lower
32.49
20, 2σ
50 / 200 cross
Death
33.00 vs 36.26
Trend bias
Above 200
+0.83%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.04
Less volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
38.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-52.6%
Peak to trough
Max drawdown 5Y
-88.0%
Peak to trough
ATR 14
0.68
1.86% of price
Beta (reported)
1.35
5Y monthly, from filing
Dividends & splits
Forward rate$0.63 / yr
Forward yield1.72%
5-year avg yield1.13%
Payout ratio43.80%
Ex-dividend dateMar 27, 2026
Next pay dateJun 2, 2017
Last split—
Split date—
Headlines
ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights
PR Newswire · 4d ago
Carl Zeiss Meditec Q3 Earnings Call Highlights
MarketBeat · 16d ago
ZEISS Meditec Selects Atlas® System from Nirrin Technologies to Modernize Hyaluronic Acid Manufacturing Workflows
Business Wire · 54d ago
ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing
PR Newswire · 66d ago
ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units
PR Newswire · 67d ago
ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens
PR Newswire · 73d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.